Skip to Content

Nafarelin Disease Interactions

There are 6 disease interactions with nafarelin:

Major

Cetrorelix (Includes Nafarelin) ↔ Severe Renal Impairment

Severe Potential Hazard, Moderate plausibility

Applies to: Renal Dysfunction

The use of cetrorelix is contraindicated in patients with severe renal impairment.

Major

Nafarelin Nasal (Includes Nafarelin) ↔ Abnormal Vaginal Bleeding

Severe Potential Hazard, High plausibility

Applies to: Abnormal Uterine Bleeding

The use of nafarelin nasal is contraindicated in patients with undiagnosed, abnormal vaginal bleeding. Patients should be evaluated to ensure that neoplastic lesions are not present.

References

  1. "Product Information. Synarel Nasel Solution (nafarelin nasal)." Searle, Chicago, IL.
Moderate

Cetrorelix (Includes Nafarelin) ↔ Severe Allergies

Moderate Potential Hazard, Moderate plausibility

Applies to: Allergies

Cases of hypersensitivity reactions including anaphylaxis have been reported during post marketing surveillance. A severe anaphylactic reaction in a patient was reported after months of administration. Special care should be taken in women with signs and symptoms of active allergic conditions or known history of allergic predisposition. Treatment with cetrorelix is not advised in women with severe allergic conditions.

Moderate

Nafarelin (Includes Nafarelin) ↔ Seizures

Moderate Potential Hazard, Moderate plausibility

Applies to: Seizures, Brain/Intracranial Tumor, Cerebral Vascular Disorder

Postmarketing reports of convulsions have been observed in patients receiving GnRH agonists. These have included patients with a history of seizures, epilepsy, cerebrovascular disorder, central nervous anomalies such as tumors, and patients receiving concomitant medications that have been associated with convulsions. Convulsions have also been reported in patients with none of these conditions. Caution is advised when administering nafarelin to patients with any of these conditions.

Moderate

Nafarelin Nasal (Includes Nafarelin) ↔ Bone Density Loss

Moderate Potential Hazard, High plausibility

Applies to: Osteoporosis, Alcoholism

Nafarelin induces a hypoestrogenic effect that results in a small loss in bone density. Therapy with nafarelin should be administered cautiously in patients with major risk factors for decreased bone mineral content, such as chronic alcohol and/or tobacco use, a strong family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, corticosteroids).

References

  1. "Product Information. Synarel Nasel Solution (nafarelin nasal)." Searle, Chicago, IL.
Moderate

Nafarelin Nasal (Includes Nafarelin) ↔ Ovarian Cysts

Moderate Potential Hazard, Moderate plausibility

Applies to: Adrenal Tumor

Nafarelin therapy induces a release of pituitary gonadotropins (LH and FSH). Ovarian cysts or enlargement of existing ovarian cysts (primarily in women with polycystic ovarian disease) have been reported during the first months of treatment. Spontaneous resolution generally occurs in 4 to 6 weeks of therapy, but some cases require discontinuation of nafarelin therapy.

References

  1. "Product Information. Synarel Nasel Solution (nafarelin nasal)." Searle, Chicago, IL.

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2018 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide